Table 1.

Transplantation of bone marrow cells from mice with imatinib treated Mx1-Cre;H/P;A/E-induced MPNs

Donor Cell No.	Cell Population*	Donor (n)	Fraction of Recipients with MPN (%)
5	LT-HSC	2	12/23 (52%)
50	LT-HSC	2	12/43 (83%)
50	LSK**	2	0/15 (0%)
5,000	LSK	2	2/14 (14%)
50	LK***	3	0/15 (0%)
5,000	LK	3	0/15 (0%)
2,000,000	WBM	2	10/30 (33%)

^*H/P;A/E diseased mice were treated for 14 days with imatinib prior to transplant of their bone marrow cells into lethally irradiated recipient mice. This was necessary because when the mice were not treated, the majority of diseased cells were terminally differentiated neutrophils that diluted out any transplantable cells in the bone marrow. In fact, LT-HSCs are difficult to detect in diseased bone marrow. WBM or FACS isolated populations were co-transplanted with 200,000 wild type bone marrow protective cells.

^**LSK=Lin-Sca⁺Kit⁺ is a population in wild type mice known to contain LT-HSC, ST-HSC and MPP early progenitors.

^***LK=Lin-Sca-Kit⁺ is a population of cells in the wild type mice known to contain CMP, MEP, and GMP committed progenitors.